Everolimus induces Met inactivation by disrupting the FKBP12/Met complex

Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellul...

Descripción completa

Detalles Bibliográficos
Autores principales: Raimondo, Lucia, D'Amato, Valentina, Servetto, Alberto, Rosa, Roberta, Marciano, Roberta, Formisano, Luigi, Mauro, Concetta Di, Orsini, Roberta Clara, Cascetta, Priscilla, Ciciola, Paola, De Maio, Ana Paula, Di Renzo, Maria Flavia, Cosconati, Sandro, Bruno, Agostino, Randazzo, Antonio, Napolitano, Filomena, Montuori, Nunzia, Veneziani, Bianca Maria, Placido, Sabino De, Bianco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129993/
https://www.ncbi.nlm.nih.gov/pubmed/27223077
http://dx.doi.org/10.18632/oncotarget.9484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129993/
https://www.ncbi.nlm.nih.gov/pubmed/27223077
http://dx.doi.org/10.18632/oncotarget.9484

Ejemplares similares